From Helse Bergen.


​RituxME is a multicentre study conducted in five study centres in Norway: the Oncology Department at Haukeland University Hospital, the ME/CFS Centre at Oslo University Hospital (Aker), the Dept of Medicine at Notodden Hospital, the Dept. of Pain and Complex Disorders at St. Olav’s Hospital in Trondheim, and the Division of Rehabilitation Services at the University Hospital of North Norway in Tromsø.
The purpose of the study is to confirm or disprove the results from two smaller phase II studies, which have indicated improvement in symptoms in a subgroup of ME patients after rituximab treatment.


The study is randomized, double-blind and placebo controlled. This means that out of 152 participants, half will receive treatments with rituximab and the other half will be treated with placebo (saline). The treatments are allocated at random, and neither patient nor doctor is informed of which intervention group the patient is allocated to.


To read the rest of this story, click on the link below:


Link to Rituximab story

Leave a Reply

The York ME Community © 2015
Powered by Live Score & Live Score App